DrugPatentWatch Database Preview
Pembrolizumab - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for pembrolizumab
| Tradenames: | 1 |
| Patents: | 131 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for pembrolizumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for pembrolizumab |
Recent Clinical Trials for pembrolizumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Oklahoma | Phase 2 |
| Thomas Jefferson University | Phase 1/Phase 2 |
| Brooklyn ImmunoTherapeutics, LLC | Phase 2 |
Recent Litigation for pembrolizumab
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| Genome & Company | 2018-10-02 |
Pharmacology for pembrolizumab
| Mechanism of Action | Programmed Death Receptor-1-directed Antibody Interactions |
Patent Text Search: US Patents for pembrolizumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Yeda Research and Development Co. Ltd (Rehovot, IL) | 2034-03-12 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Flexus Biosciences, Inc. (Princeton, NJ) | 2034-11-05 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | The Regents of the University of California (Oakland, CA) | 2035-02-24 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) | 2035-07-31 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | 2039-02-26 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Plexxikon Inc. (Berkeley, CA) | 2035-09-21 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for pembrolizumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3483183 | Start Trial |
| China | 107735104 | Start Trial |
| Japan | 2018515482 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014163684 | Start Trial |
| European Patent Office | 1519958 | Start Trial |
| Canada | 2966356 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
